Aspirin following PCI: Too much of a good thing?

European Heart Journal

Volumn 30, Issue 8, 2009, Pages 882-884

  Steinhubl, Steven R ^a,b   Berger, Peter B ^a  

^a GEISINGER MEDICAL CENTER   (United States)

^b Medicines Company   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1; PLACEBO;

BLEEDING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG ELUTING STENT; EDITORIAL; ENZYME INHIBITION; HUMAN; ISCHEMIC HEART DISEASE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS;

EID: 65249090809     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehp105     Document Type: Editorial

References (21)

1. USFaDA. Final rule for professional labeling of aspirin, buffered aspirin, and aspirin in combination with antacid drug products. Federal Register: October 23, 1998 (Volume 63, Number 205). http://www.fda.gov/ohrms/ dockets/98fr/102398c.txt (accessed April 26 2008).
2. Campbell CL, Smyth S, Montalescot G, Steinhubl SR. Aspirin dose for the prevention of cardiovascular disease: a systematic review. JAMA 2007;297:2018-2024.
3. Schwartz L, Bourassa MG, Lesperance J, Aldridge HE, Kazim F, Salvatori VA, Henderson M, Bonan R, David PR. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719.
4. White CW, Chaitman B, Knudson ML, Chisholm RJ, and the Ticlopidine Study Group. Antiplatelet agents are effective in reducing the acute ischemic complications of angioplasty but do not prevent restenosis: results from the ticlopidine trial. Coronary Artery Dis 1991;2:757-767.
5. Savage MP, Goldberg S, Bove AA, Deutsch E, Vetrovec G, Macdonald RG, Bass T, Margolis JR, Whitworth HB, Taussig A, Hirshfeld JW, Cowley M, Hill JA, Marks RG, Fischman DL, Handberg E, Herrmann H, Pepine CJ, for the M-HEART II Study Group. Effect of thromboxane A2 blockade on clinical outcome and restenosis after successful coronary angioplasty. Multi-Hospital Eastern Atlantic Restenosis Trial (M-HEART II). Circulation 1995;92: 3194-3200.
6. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davi G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 1985;72:1177-1184.
7. Montalescot G, Maclouf J, Drobinski G, Salloum J, Grosgogeat Y, Thomas D. Eicosanoid biosynthesis in patients with stable angina: beneficial effects of very low dose aspirin. J Am Coll Cardiol 1994;24:33-38.
8. Jolly SS, Pogue J, Haladyn K, Peters RJG, Fox KAA, Avezum A, Gersh BJ, Rupprecht HJ, Yusuf S, Mehta SR. Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. Eur Heart J 2009;30:900-907. First published on 26 September 2008. doi:10.1093/eurheartj/ehn417.
9. Alberts M, Bergman D, Molner E, Jovanovic B, Ushiwata I, Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-178.
10. Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007;153:175-181.
11. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J 2007;28:1702-1708.
12. Topol EJ, Leya F, Pinkerton CA, Whitlow PL, Hofling B, Simonton CA, Masden RR, Serruys PW, Leon MB, Williams DO et al. A comparison of directional arthrectomy with coronary angioplasty in patients with coronary artery disease. N Engl J Med 1993;329:221-227.
13. Serruys PW, De Jaegere P, Kiemeneij F, Magaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M-A, for the Benestent Study Group. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331:489-495.
14. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish DR, Colombo A, Brinker J, Moses J, Shaknovich A, Hirschfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators. A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496- 501.
15. Schomig A, Neumann F, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzman-Roth E, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after placement of coronary-artery stents. N Engl J Med 1996;334:1084-1089.
16. Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE, for the Stent Antic-oagulation Restenosis Study (STARS) Investigators. A clinical trial comparing three antithrombotic-drug regimens following coronary artery stenting. N Eng J Med 1998;339:1665-1671.
17. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revasculariza-tion. N Engl J Med 2002;346:1773-1780.
18. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349:1315-1323.
19. Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
20. Stone GW, Ellis SG, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
21. Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J, Farhat N, Mahaffey KW, Cutlip DE, Fitzgerald PJ, Sood P, Su X, Lansky AJ. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299:1903- 1913.